New cancer pill targets KRAS and EGFR mutations in early human trial
NCT ID NCT05163028
Summary
This early-stage study is testing a new oral medication called HBI-2376 in people with advanced solid tumors that have specific KRAS or EGFR mutations. The main goals are to find the highest safe dose of the drug and to understand how the body absorbs and processes it. The trial will enroll up to 42 adults whose cancer has progressed despite standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BRCR Medical Center
Plantation, Florida, 33322, United States
-
California Cancer Associates for Research and Excellence, Inc. (cCare)
Encinitas, California, 92024, United States
-
California Cancer Associates for Research and Excellence, Inc. (cCare)
San Marcos, California, 92069, United States
-
City of Hope
Duarte, California, 91010, United States
-
Gabrail Cancer Center
Canton, Ohio, 44718, United States
-
Orlando Health, Inc.
Orlando, Florida, 32806, United States
-
Pan American Center for Oncology Trials (PanOncology Trials)
Rio Piedras, Puerto Rico, 00935, Puerto Rico
-
Providence Medical Foundation
Fullerton, California, 92835, United States
-
Sarcoma Oncology
Santa Monica, California, 90403, United States
-
Texas Oncology - Tyler
Tyler, Texas, 75702, United States
-
UCLA Hematology/Oncology
Santa Monica, California, 90404, United States
-
Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States
Conditions
Explore the condition pages connected to this study.